Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.fdcindia.com | |
Market Cap | 4,256.42 Cr. | |
Enterprise Value(EV) | 4,237.04 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 10.47 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 24.38 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.41 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 127.76 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 2.00 | Calculated using Price: 255.30 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 16.59 Cr. | 165,910,084 Shares |
FaceValue | 1 | |
Company Profile | ||
FDC Limited is among India's leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialised formulations, and among the world's foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Over its long history of 85 years, the Company has maintained a distinguished reputation for high-quality, affordable products and built a market-leading brand portfolio. |
1 Day |
|
-0.35% |
1 Week |
|
+0.24% |
1 Month |
|
-2.78% |
3 Month |
|
-5.97% |
6 Month |
|
-3.37% |
1 Year |
|
-0.62% |
2 Year |
|
-10.64% |
5 Year |
|
+1.41% |
10 Year |
|
+177.05% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 16.63 | 16.64 | 16.72 | 16.03 | 13.63 | 12.48 | 16.03 | 18.36 | 11.71 | |
Return on Capital Employed (%) | 27.12 | 23.02 | 23.11 | 21.51 | 19.00 | 17.49 | 21.56 | 23.74 | 15.78 | |
Return on Assets (%) | 13.26 | 13.34 | 13.97 | 12.00 | 9.03 | 8.20 | 10.43 | 11.85 | 7.59 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 845 | 936 | 1,082 | 1,270 | 1,276 | 1,445 | 1,547 | 1,734 | 1,957 | 1,901 | |
Non Curr. Liab. | 31 | 24 | 20 | 217 | 211 | 229 | 315 | 300 | 391 | 33 | |
Curr. Liab. | 196 | 188 | 163 | 389 | 480 | 497 | 565 | 622 | 690 | 365 | |
Minority Int. | 0 | 0 | 0 | ||||||||
Equity & Liab. | 1,072 | 1,148 | 1,266 | 1,876 | 1,968 | 2,172 | 2,427 | 2,655 | 3,038 | 2,297 | |
Non Curr. Assets | 619 | 646 | 742 | 958 | 977 | 1,113 | 1,181 | 1,303 | 1,620 | 1,281 | |
Curr. Assets | 452 | 502 | 523 | 918 | 991 | 1,058 | 1,245 | 1,352 | 1,418 | 1,016 | |
Misc. Exp. not W/O | 0 | ||||||||||
Total Assets | 1,072 | 1,148 | 1,266 | 1,876 | 1,968 | 2,172 | 2,427 | 2,655 | 3,038 | 2,297 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 846 | 889 | 994 | 1,014 | 1,075 | 1,091 | 1,344 | 1,333 | 1,528 | 1,690 | |
Other Income | 42 | 46 | 39 | 50 | 51 | 43 | 69 | 97 | 76 | 60 | |
Total Income | 888 | 935 | 1,033 | 1,064 | 1,126 | 1,134 | 1,413 | 1,430 | 1,604 | 1,750 | |
Total Expenditure | -641 | -691 | -766 | -770 | -848 | -860 | -1,051 | -999 | -1,274 | -1,476 | |
PBIDT | 246 | 244 | 268 | 294 | 278 | 274 | 362 | 431 | 330 | 274 | |
Interest | -3 | -2 | -1 | -1 | -1 | -1 | -3 | -3 | -3 | -4 | |
Depreciation | -25 | -39 | -34 | -35 | -35 | -33 | -37 | -38 | -37 | -38 | |
Taxation | -83 | -56 | -63 | -63 | -67 | -67 | -80 | -87 | -73 | -58 | |
Exceptional Items | -6 | -1 | -2 | ||||||||
PAT | 135 | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 174 | |
Minority Interest | 0 | 0 | 0 | ||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 135 | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 174 | |
Adjusted EPS | 8 | 8 | 9 | 11 | 10 | 10 | 14 | 18 | 13 | 10 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 150 | 150 | 128 | 174 | 154 | 150 | 112 | 250 | 207 | 162 | |
Cash Fr. Inv. | -107 | -55 | -89 | -73 | -144 | 20 | -120 | -98 | -77 | -145 | |
Cash Fr. Finan. | -63 | -75 | -48 | -97 | 0 | -169 | 0 | -142 | -129 | -10 | |
Net Change | -20 | 19 | -9 | 4 | 11 | 1 | -8 | 10 | 1 | 7 | |
Cash & Cash Eqvt | 4 | 23 | 15 | 16 | 27 | 28 | 20 | 30 | 30 | 38 |
Thu, 30 Mar 2023
Closure of Trading Window Pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 & Amendments thereon and in compliance with Companys Code of Conduct for the Prevention of Insider Trading and Code of Fair Disclosure the Trading Window for dealing in Securities of the Company for all the Designated Persons Connected Persons and their Immediate Relative(s) shall remain closed from Saturday April 01 2023 until 48 hours after the declaration of the Audited Financial Results of the Company for the quarter and year ended March 31 2023.The date of Board Meeting of the Company for consideration and approval of the Audited Financial Results for the quarter and year ended March 31 2023 will be intimated in duecourse. |
Mon, 27 Mar 2023
US - FDA Inspection At Company'S Manufacturing Facility Located At Roha Dist.- Raigad Maharashtra India. This is to inform you that our manufacturing unit located at Roha Dist.- Raigad Maharashtra that manufactures Active Pharmaceutical Ingredient (APIs) products has been inspected by US FDA from 20th March 2023 to 24th March 2023. The said audit has been successfully completed by the US FDA with No observations (Zero 483s). The Active Pharmaceutical Ingredients (APIs) product manufactured at the above facility continues to be marketed in USA. |
Mon, 13 Feb 2023
US - FDA Inspection At Company'S Manufacturing Facility Located At Waluj Aurangabad. This is to inform you that our manufacturing plant located at B-8 MIDC Industrial Area Waluj Aurangabad Maharashtra which manufactures sterile ophthalmic products has been inspected by US FDA from 06th February to 12th February 2023. The said audit has been successfully completed by the US FDA with No observations (Zero 483s). The audit was carried out for the sterile ophthalmic products being marketed inthe US. |
Fri, 31 Mar 2023 |
|
|
|
|
Wed, 29 Mar 2023 |
|